EA201790919A1 - Спиротиазолоны - Google Patents

Спиротиазолоны

Info

Publication number
EA201790919A1
EA201790919A1 EA201790919A EA201790919A EA201790919A1 EA 201790919 A1 EA201790919 A1 EA 201790919A1 EA 201790919 A EA201790919 A EA 201790919A EA 201790919 A EA201790919 A EA 201790919A EA 201790919 A1 EA201790919 A1 EA 201790919A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorders
present
spirothozolones
obsessive
schizophrenia
Prior art date
Application number
EA201790919A
Other languages
English (en)
Inventor
Козимо Доленте
Бернард Фашинг
Валери Рунц-Шмитт
Патрик Шнидер
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA201790919A1 publication Critical patent/EA201790919A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены спиротиазолоны, которые действуют в качестве модуляторов рецепторов V1a, и, в частности, антагонистов рецепторов V1a, их производство, содержащие их фармацевтические композиции и их применение в качестве лекарственных средств. Соединения настоящего изобретения применяют в качестве терапевтических средств периферического и центрального действия при нарушении секреции вазопрессина, тревожности, депрессивных расстройствах, обсессивно-компульсивном расстройстве, расстройствах аутистического спектра, шизофрении, агрессивном поведении и нарушениях сна со сдвигом фазы, в частности синдрома смены часовых поясов.
EA201790919A 2014-11-14 2015-11-11 Спиротиазолоны EA201790919A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14193294 2014-11-14
PCT/EP2015/076278 WO2016075181A1 (en) 2014-11-14 2015-11-11 Spiro-thiazolones

Publications (1)

Publication Number Publication Date
EA201790919A1 true EA201790919A1 (ru) 2017-08-31

Family

ID=51904773

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790919A EA201790919A1 (ru) 2014-11-14 2015-11-11 Спиротиазолоны

Country Status (21)

Country Link
US (1) US10092551B2 (ru)
EP (1) EP3218381B1 (ru)
JP (1) JP6629855B2 (ru)
KR (1) KR20170084047A (ru)
CN (1) CN107001382B (ru)
AR (1) AR102633A1 (ru)
AU (1) AU2015345102A1 (ru)
BR (1) BR112017007363A2 (ru)
CA (1) CA2963188A1 (ru)
CL (1) CL2017001231A1 (ru)
CO (1) CO2017002963A2 (ru)
CR (1) CR20170195A (ru)
EA (1) EA201790919A1 (ru)
IL (1) IL250999A0 (ru)
MX (1) MX2017006294A (ru)
PE (1) PE20170671A1 (ru)
PH (1) PH12017500891A1 (ru)
SG (1) SG11201703604VA (ru)
TW (1) TW201625642A (ru)
WO (1) WO2016075181A1 (ru)
ZA (1) ZA201701914B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234252A1 (en) * 2005-05-18 2008-09-25 Pfizer Inc Compounds Useful in Therapy
EP2102207B1 (en) * 2006-12-07 2010-06-02 F.Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
EP2104677B1 (en) * 2007-01-12 2011-12-07 F. Hoffmann-La Roche AG Spiropiperidine glycinamide derivatives
CA2741018A1 (en) * 2008-11-13 2010-05-20 F. Hoffmann-La Roche Ag Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes
US20150376198A1 (en) * 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential

Also Published As

Publication number Publication date
PH12017500891A1 (en) 2017-11-06
EP3218381A1 (en) 2017-09-20
KR20170084047A (ko) 2017-07-19
CA2963188A1 (en) 2016-05-19
TW201625642A (zh) 2016-07-16
AR102633A1 (es) 2017-03-15
CR20170195A (es) 2017-05-31
CL2017001231A1 (es) 2018-01-12
MX2017006294A (es) 2017-08-21
US10092551B2 (en) 2018-10-09
CO2017002963A2 (es) 2017-07-19
IL250999A0 (en) 2017-04-30
EP3218381B1 (en) 2019-01-23
AU2015345102A1 (en) 2017-03-30
WO2016075181A1 (en) 2016-05-19
BR112017007363A2 (pt) 2017-12-19
SG11201703604VA (en) 2017-06-29
JP2017533933A (ja) 2017-11-16
PE20170671A1 (es) 2017-05-22
JP6629855B2 (ja) 2020-01-15
US20170246153A1 (en) 2017-08-31
ZA201701914B (en) 2018-12-19
CN107001382B (zh) 2019-10-25
CN107001382A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
NZ737399A (en) Ccr2 modulators
EA201690629A1 (ru) Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201591648A1 (ru) Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4
MX2017005484A (es) Compuestos antagonistas del receptor de dopamina d3.
IL248118A0 (en) Converted inanone compounds as gpr119 regulators for the treatment of diabetes, obesity, dyslipidemia and related diseases
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
EA201490519A1 (ru) Селективные модуляторы рецепторов андрогенов
EA201690179A1 (ru) Антагонисты рецептора v1a для лечения расстройств, связанных со сдвигом фазы сна
PH12016501613A1 (en) Pyrazines modulators of gpr6
EA201691189A1 (ru) Спиро-оксазолоны
CL2015000580A1 (es) Compuestos derivados de pirazol carboxamida, moduladores taar; composicion farmaceutica; proceso para obtenerlos; y su uso para el tratamiento terapeutico o profilactico de la depresion, trastornos de ansiedad, trastorno de hiperactividad con deficit de atencion, trastornos psicoticos, esquizofrenia y parkinson, entre otros.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
MX2016009501A (es) Espiro-oxazolonas.
EA201790919A1 (ru) Спиротиазолоны
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
MX346252B (es) Procedimiento para producir antagonistas de los receptores del peptido relacionado con el gen de calcitonina.
TR201905436T4 (tr) Terapötik bileşikler olarak yeni ep4 agonistleri.
TH169399B (th) สไพโร-ออกซาโซโลน